• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Eye Care Launch Chaos

























This is a comedy forum. What, you didn't know?! Get with the program. After looking into my crystal ball, I predict vuity isn't the winner you hoped it would be. #winning is everything; not your eyes. @Joe.B.inCincinnati
 
























Nope getting vuity

Ha, a third rep taking a $70 drug that the cheddar heads inside mis-launched so badly that we don't even have literature yet?

We're two months into this launch and most of our speakers still have low single digit scripts... if any. All the bimbos running this can come up with "oh look, the number of scripts goes up with the number of writers"... yea, no crap, coming from nothing anything will bring up the numbers.
 




Ha, a third rep taking a $70 drug that the cheddar heads inside mis-launched so badly that we don't even have literature yet?

We're two months into this launch and most of our speakers still have low single digit scripts... if any. All the bimbos running this can come up with "oh look, the number of scripts goes up with the number of writers"... yea, no crap, coming from nothing anything will bring up the numbers.
I respectfully disagree. There is a path for the green. What you don’t understand is the enormity of this market. I challenge you to look at the number of patients with presbyopia.
 
























This is a serious shit show. Zero direction from upper mgmt just manage to a call panel that’s flawed from day 1.

Nobody know what were actually supposed to be doing... no communication from anyone above the DM level. Just reach and frequency; this will be a failure case study in some university textbook 10 years down the road.

It's crazy but I know a decent number of people who have already started looking for new jobs.